Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts

Epigenetics

Volumn 10, Issue 3, 2015, Pages 237-246

  Srivastava, Pragya ^a   Paluch, Benjamin E ^a   Matsuzaki, Junko ^a   James, Smitha R ^a   Collamat Lai, Golda ^a   Taverna, Pietro ^b   Karpf, Adam R ^c   Griffiths, Elizabeth A ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b ASTEX PHARMACEUTICALS   (United Kingdom)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Cancer germline genes; Cancer testis antigens; DNA methylation; DNA methyltransferase inhibitors; Epigenetics; Epithelial ovarian cancer; Immune modulation; SGI 110

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CANCER TESTIS ANTIGEN; DNA METHYLTRANSFERASE INHIBITOR; GENOMIC DNA; INTERCELLULAR ADHESION MOLECULE 1; MELANOMA ANTIGEN; AZACITIDINE; ENZYME INHIBITOR; METHYLTRANSFERASE; SGI-110; TUMOR ANTIGEN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CELL VIABILITY ASSAY; CONTROLLED STUDY; DNA METHYLATION; FEMALE; FLOW CYTOMETRY; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOMODULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; OVARY CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; TUMOR GROWTH; WESTERN BLOTTING; XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; DRUG EFFECTS; GENETICS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; SCID MOUSE; T LYMPHOCYTE; TUMOR CELL LINE;

MURINAE;

ANIMALS; ANTIGENS, NEOPLASM; AZACITIDINE; CELL LINE, TUMOR; DNA METHYLATION; ENZYME INHIBITORS; HETEROGRAFTS; HUMANS; METHYLTRANSFERASES; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; T-LYMPHOCYTES;

EID: 84925297064     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.1080/15592294.2015.1017198     Document Type: Article

References (45)

1. Odunsi K, Jungbluth AA, Stockert E, Qian F, Gnjatic S, Tammela J, Intengan M, Beck A, Keitz B, Santiago D, et al. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res 2003; 63:6076-83; PMID:14522938.
2. Woloszynska-Read A, Mhawech-Fauceglia P, Yu J, Odunsi K, Karpf AR. Intertumor and intratumor NYESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer. Clin Cancer Res 2008; 14:3283-90; PMID:18519754; http://dx.doi.org/10.1158/1078-0432.CCR-07-5279.
3. Imura M, Yamashita S, Cai LY, Furuta J, Wakabayashi M, Yasugi T, Ushijima T. Methylation and expression analysis of 15 genes and three normally-methylated genes in 13 ovarian cancer cell lines. Cancer Lett 2006; 241:213-20; PMID:16303245; http://dx.doi.org/10.1016/j.canlet.2005.10.010.
4. Gnjatic S, Atanackovic D, Jager E, Matsuo M, Selvakumar A, Altorki NK, Maki RG, Dupont B, Ritter G, Chen YT, et al. Survey of naturally occurring CD4C T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses. Proc Natl Acad Sci U S A 2003; 100:8862-7; PMID:12853579; http://dx.doi.org/10.1073/pnas.1133324100.
5. Stone B, Schummer M, Paley PJ, Thompson L, Stewart J, Ford M, Crawford M, Urban N, O’Briant K, Nelson BH. Serologic analysis of ovarian tumor antigens reveals a bias toward antigens encoded on 17q. Int J Cancer 2003; 104:73-84; PMID:12532422; http://dx.doi.org/10.1002/ijc.10900.
6. Huarte E, Karbach J, Gnjatic S, Bender A, Jager D, Arand M, Atanackovic D, Skipper J, Ritter G, Chen YT, et al. HLA-DP4 expression and immunity to NYESO-1: Correlation and characterization of cytotoxic CD4C CD25-CD8-T cell clones. Cancer Immun 2004; 4:15; PMID:15600300.
7. Qian F, Gnjatic S, Jager E, Santiago D, Jungbluth A, Grande C, Schneider S, Keitz B, Driscoll D, Ritter G, et al. Th1/Th2 CD4C T cell responses against NYESO-1 in HLA-DPB1*0401/0402 patients with epithelial ovarian cancer. Cancer Immun 2004; 4:12; PMID:15521719.
8. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, et al. Intraepithelial CD8C tumor-infiltrating lymphocytes and a high CD8C/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005; 102:18538-43; PMID:16344461; http://dx.doi.org/10.1073/pnas.0509182102.
9. Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman EW, Pan L, Ritter G, Villella J, Thomas B, et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A 2007; 104:12837-42; PMID:17652518; http://dx.doi.org/10.1073/pnas.0703342104.
10. Karbach J, Gnjatic S, Bender A, Neumann A, Weidmann E, Yuan J, Ferrara CA, Hoffmann E, Old LJ, Altorki NK, et al. Tumor-reactive CD8C T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and montanide ISA-51: Association with survival. Int J Cancer 2010; 126:909-18; PMID:19728336; http://dx.doi.org/10.1002/ijc.24850.
11. Odunsi K, Matsuzaki J, Karbach J, Neumann A, Mhawech-Fauceglia P, Miller A, Beck A, Morrison CD, Ritter G, Godoy H, et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci U S A 2012; 109: 5797-802; PMID:22454499; http://dx.doi.org/10.1073/pnas.1117208109.
12. Sabbatini P, Tsuji T, Ferran L, Ritter E, Sedrak C, Tuballes K, Jungbluth AA, Ritter G, Aghajanian C, Bell-McGuinn K, et al. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res 2012; 18:6497-508; PMID:23032745; http://dx.doi. org/10.1158/1078-0432.CCR-12-2189.
13. Nicholaou T, Chen W, Davis ID, Jackson HM, Dimopoulos N, Barrow C, Browning J, Macgregor D, Williams D, Hopkins W, et al. Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX. Cancer Immunol Immunother 2011; 60:1625-37; PMID:21698545; http://dx.doi.org/10.1007/s00262-011-1041-3.
14. De Smet C, Loriot A, Boon T. Promoter-dependent mechanism leading to selective hypomethylation within the 50 region of gene MAGE-A1 in tumor cells. Mol Cell Biol 2004; 24:4781-90; PMID:15143172; http://dx.doi.org/10.1128/MCB.24.11.4781-4790.2004.
15. Akers SN, Odunsi K, Karpf AR. Regulation of cancer germline antigen gene expression: Implications for cancer immunotherapy. Future Oncol 2010; 6:717-32; PMID:20465387; http://dx.doi.org/10.2217/fon.10.36.
16. Loriot A, De Plaen E, Boon T, De Smet C. Transient down-regulation of DNMT1 methyltransferase leads to activation and stable hypomethylation of MAGE-A1 in melanoma cells. J Biol Chem 2006; 281:10118-26; PMID:16497664; http://dx.doi.org/M510469200 [pii].
17. Weber J, Salgaller M, Samid D, Johnson B, Herlyn M, Lassam N, Treisman J, Rosenberg SA. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-20-deoxycytidine. Cancer Res 1994; 54:1766-71; PMID:7511051.
18. Karpf AR, Lasek AW, Ririe TO, Hanks AN, Grossman D, Jones DA. Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-20-deoxycytidine. Mol Pharmacol 2004; 65:18-27; PMID:14722233; http://dx.doi.org/10.1124/mol.65.1.18.
19. Srivastava P, Paluch BE, Matsuzaki J, James SR, Collamat-Lai G, Karbach J, Nemeth MJ, Taverna P, Karpf AR, Griffiths EA. Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts. Leuk Res 2014; 38:1332-41; PMID:25260825; http://dx.doi.org/10.1016/j. leukres.2014.09.001.
20. Adair SJ, Hogan KT. Treatment of ovarian cancer cell lines with 5-aza-20-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules. Cancer Immunol Immunother 2009; 58:589-601; PMID:18791715; http://dx.doi.org/10.1007/s00262-008-0582-6.
21. Coral S, Parisi G, Nicolay HJ, Colizzi F, Danielli R, Fratta E, Covre A, Taverna P, Sigalotti L, Maio M. Immunomodulatory activity of SGI-110, a 5-aza-20-deoxycytidine-containing demethylating dinucleotide. Cancer Immunol Immunother 2013; 62:605-14; PMID:23138873; http://dx.doi.org/10.1007/s00262-012-1365-7.
22. Karpf AR. A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy. Epigenetics 2006; 1:116-20; PMID:17786175.
23. Griffiths EA, Gore SD. Epigenetic therapies in MDS and AML. Adv Exp Med Biol 2013; 754:253-83; PMID:22956506; http://dx.doi.org/10.1007/978-1-4419-9967-2_13.
24. Samlowski WE, Leachman SA, Wade M, Cassidy P, Porter-Gill P, Busby L, Wheeler R, Boucher K, Fitzpatrick F, Jones DA, et al. Evaluation of a 7-day continuous intravenous infusion of decitabine: Inhibition of promoter-specific and global genomic DNA methylation. J Clin Oncol 2005; 23:3897-905; PMID:15753459; http://dx.doi.org/JCO.2005.06.118 [pii].
25. Sessa C, Suinink W, Stoter G, Renard J, Cavalli F. Phase II study of 5-aza-20-deoxycytidine in advanced ovarian carcinoma. the EORTC early clinical trials group. Eur J Cancer 1990; 26:137-8; PMID:1691012.
26. Bellet RE, Catalano RB, Mastrangelo MJ, Berd D. Phase II study of subcutaneously administered 5-azacytidine (NSC-102816) in patients with metastatic malignant melanoma. Med Pediatr Oncol 1978; 4:11-5; PMID:75498.
27. Yoo CB, Jeong S, Egger G, Liang G, Phiasivongsa P, Tang C, Redkar S, Jones PA. Delivery of 5-aza-20-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res 2007; 67:6400-8; PMID:17616700; http://dx.doi. org/67/13/6400 [pii].
28. Griffiths EA, Choy G, Redkar S, Taverna P, Azab M, Karpf AR. SGI-110. DNA methyltransferase inhibitor, oncolytic. Drugs Fut 2013; 38:535.
29. Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 2008; 123:8-13; PMID:18425818; http://dx.doi.org/10.1002/ijc.23607.
30. Woloszynska-Read A, Zhang W, Yu J, Link PA, Mhawech-Fauceglia P, Collamat G, Akers SN, Ostler KR, Godley LA, Odunsi K, et al. Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: Association with the BORIS/CTCF expression ratio and advanced stage. Clin Cancer Res 2011; 17:2170-80; PMID:21296871; http://dx.doi.org/10.1158/1078-0432.CCR-10-2315.
31. Kantarjian H, Roboz G, Rizzieri D, Stock W, O’Connell C, Griffiths EA, Yee K, Tibes R, Garcia-Manero G, Ravandi F, et al. Results from the dose escalation phase of a randomized phase 1–2 first-in-human (FIH) study of SGI-110, a novel low volume stable subcutaneous (SQ) second generation hypomethylating agent (HMA) in patients with relapsed/refractory MDS and AML. Blood 2012; 120:414.
32. De Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora JP, De Smet C, Brasseur F, van der Bruggen P, Lethe B, Lurquin C. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 1994; 40:360-9; PMID:7927540.
33. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, Koup RA. Sensitive and viable identification of antigen-specific CD8C T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003; 281:65-78; PMID:14580882.
34. Oflazoglu E, Elliott M, Takita H, Ferrone S, Henderson RA, Repasky EA. Adoptively transferred human lung tumor specific cytotoxic T cells can control autologous tumor growth and shape tumor phenotype in a SCID mouse xenograft model. J Transl Med 2007; 5:29; PMID:17592641; http://dx.doi.org/1479-5876-5-29 [pii].
35. Natsume A, Wakabayashi T, Tsujimura K, Shimato S, Ito M, Kuzushima K, Kondo Y, Sekido Y, Kawatsura H, Narita Y, et al. The DNA demethylating agent 5-aza-20-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma. Int J Cancer 2008; 122:2542-53; PMID:18240144; http://dx.doi. org/10.1002/ijc.23407.
36. Fang F, Munck J, Tang J, Taverna P, Wang Y, Miller DF, Pilrose J, Choy G, Azab M, Pawelczak KS, et al. The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer. Clin Cancer Res 2014; 20:6504-16; PMID:25316809; http://dx.doi.org/10.1158/1078-0432.CCR-14-1553.
37. Clinicaltrials.gov. A randomized, controlled, openlabel, phase 2 trial of SGI-110 and carboplatin in subjects with platinum-resistant recurrent ovarian cancer: NCT01696032. 2014; 2014.
38. Odunsi K, Matsuzaki J, James SR, Mhawech-Fauceglia P, Tsuji T, Miller A, Zhang W, Akers SN, Griffiths EA, Miliotto A, et al. Epigenetic potentiation of NYESO-1 vaccine therapy in human ovarian cancer. Cancer Immunol Res 2014; 2:37-49.
39. Matei D, Fang F, Shen C, Schilder J, Arnold A, Zeng Y, Berry WA, Huang T, Nephew KP. Epigenetic resensitization to platinum in ovarian cancer. Cancer Res 2012; 72:2197-205; PMID:22549947; http://dx.doi. org/10.1158/0008-5472.CAN-11-3909.
40. Schrump DS, Fischette MR, Nguyen DM, Zhao M, Li X, Kunst TF, Hancox A, Hong JA, Chen GA, Pishchik V, et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 2006; 12:5777-85; PMID:17020984; http://dx.doi.org/10.1158/1078-0432.CCR-06-0669.
41. Link PA, Gangisetty O, James SR, Woloszynska-Read A, Tachibana M, Shinkai Y, Karpf AR. Distinct roles for histone methyltransferases G9a and GLP in cancer germ-line antigen gene regulation in human cancer cells and murine embryonic stem cells. Mol Cancer Res 2009; 7:851-62; PMID:19531572; http://dx.doi.org/10.1158/1541-7786.MCR-08-0497.
42. Wischnewski F, Pantel K, Schwarzenbach H. Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol Cancer Res 2006; 4:339-49; PMID:16687489; http://dx.doi.org/4/5/339 [pii].
43. James SR, Cedeno CD, Sharma A, Zhang W, Mohler JL, Odunsi K, Wilson EM, Karpf AR. DNA methylation and nucleosome occupancy regulate the cancer germline antigen gene MAGEA11. Epigenetics 2013; 8:849-63; PMID:23839233; http://dx.doi.org/10.4161/epi.25500.
44. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996; 93:9821-6; PMID:8790415.
45. Li LC, Dahiya R. MethPrimer: Designing primers for methylation PCRs. Bioinformatics 2002; 18:1427-31; PMID:12424112.